Condition: NSCLC · Nintedanib · Radiation Pneumonitis · Sponsor: Second Hospital of Shanxi Medical University
This study is aimed at patients with unresectable NSCLC who take nintedanib during sequential radiotherapy to explore the incidence of radiation pneumonitis above grade 2 in the nintedanib combined with radiotherapy mode and observe safety. And will further explore the progression-free survival (PFS) and overall survival (OS) of patients treated with nintedanib in combination with radiotherapy and immunotherapy. Primary objective: To evaluate the safety of nintedanib combined with sequential radiotherapy in patients with unresectable NSCLC and the incidence of radiation pneumonitis above grade 2. Secondary objective: To evaluate the changes in lung function, progression-free survival (PFS) and overall survival (OS) in patients with unresectable NSCLC after nintedanib combined with sequential radiotherapy. Patients need to receive induction therapy, chemotherapy and/or immunotherapy for at least one cycle. Then they will receive sequential radiotherapy and nintedanib for 6 months. Finally, they will receive immunotherapy maintenance therapy for 16 cycles.
This description comes directly from the study's public registry record.
Gang Jin, Dr. · +86 351 3365422 · jingang2018@sina.com
Chen Zhang · +86 351 3365422
Always discuss trial participation with your own doctor first.
| Jincheng General Hospital | Jincheng, Shanxi, China | Recruiting |
| Jinzhong third people's hospital | Jinzhong, Shanxi, China | Recruiting |
| Frist Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
| Second Hospital of Shanxi Medical University | Taiyuan, Shanxi, China | Recruiting |
| Shanxi Bethune Hospital | Taiyuan, Shanxi, China | Recruiting |
| Shanxi Hospital of Traditional Chinese Medicine | Taiyuan, Shanxi, China | Recruiting |
| TISCO General Hospital | Taiyuan, Shanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06570317